Let's collaborate Boehringer Ingelheim

ESMO-ASIA SINGAPORE, SINGAPORE, 23–25 NOVEMBER 2018

Afatinib followed by osimertinib in real-world patients with EGFR mutation-positive NSCLC: an observational study

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A. Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer

RELATED MATERIALS

Learn more about the science behind this poster in the videos, papers and other materials below.

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

V. Hirsh. Ther Adv Med Oncol. 10(1), 1758834017753338 (2018)

Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer

T. S. Mok, Y. L. Wu, M. J. Ahn, et al. N Engl J Med. 376(7), 629-640 (2017)

Related information

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY.

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

 

image